Skip to main content

Table 3 Stage-specific three-year relative survival of patients with small cell lung carcinoma and extrapulmonary small cell carcinoma diagnosed in SEER-13 according to gender, age, and calendar year, 1992-2010*

From: A population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992–2010

  SCLC EPSCC EPSCC-to-SCLC
Stage No. RS (%) (95%CI) No. RS (%) (95%CI) RSR (95%CI)
Total         
Limited 12,070 20.7 (19.9, 21.5) 907 42.7 (39.1, 46.2) 2.06 (1.88, 2.26)‡
Distant 29,003 4.0 (3.7, 4.2) 835 6.2 (4.6, 8.1) 1.55 (1.16, 2.07)‡
Gender and age
Males, <60 years
 Limited 1,407 24.9 (22.6, 27.3) 124 37.0 (28.2, 45.7) 1.49 (1.15, 1.92)‡
 Distant 3,993 4.8 (4.2, 5.5) 121 7.8 (3.8, 13.6) 1.63 (0.85, 3.11)
Females, <60 years
 Limited 1,442 31.2 (28.7, 33.7) 251 51.8 (45.2, 58.1) 1.66 (1.43, 1.93)‡
 Distant 3,043 7.2 (6.2, 8.1) 169 11.1 (6.7, 16.8) 1.54 (0.96, 2.49)
Males, ≥60 years
 Limited 4,469 16.8 (15.6, 18.0) 312 40.3 (34.0, 46.6) 2.40 (2.02, 2.85)‡
 Distant 11,594 2.8 (2.5, 3.1) 297 3.7 (1.8, 6.7) 1.32 (0.69, 2.53)
Females, ≥60 years
 Limited 4,752 19.7 (18.5, 21.0) 220 38.8 (31.6, 45.9) 1.97 (1.62, 2.40)‡
 Distant 10,373 4.0 (3.6, 4.4) 248 4.9 (2.6, 8.4) 1.23 (0.67, 2.25)
Race and age
Whites, <60 years
 Limited 2,360 28.9 (27.1, 30.8) 282 47.0 (40.8, 52.9) 1.63 (1.41, 1.88)‡
 Distant 5,849 5.7 (5.1, 6.4) 224 10.1 (6.5, 14.7) 1.77 (1.16, 2.70)‡
Blacks, <60 years
 Limited 327 21.3 (16.9, 26.1) 44 25.1 (13.3, 38.9) 1.18 (0.67, 2.08)
 Distant 796 5.1 (3.7, 6.9) 36 10.7 (3.2, 23.5) 2.10 (0.76, 5.81)
Whites, ≥60 years
 Limited 7,887 18.5 (17.6, 19.4) 449 38.7 (33.4, 43.8) 2.09 (1.81, 2.42)‡
 Distant 18,793 3.3 (3.0, 3.6) 451 4.5 (2.7, 7.0) 1.36 (0.84, 2.21)
Blacks, ≥60 years
 Limited 699 16.5 (13.6, 19.6) 41 47.5 (30.6, 62.6) 2.88 (1.95, 4.25)‡
 Distant 1,770 3.2 (2.4, 4.2) 50 4.3 (0.8, 13.1) 1.34 (0.33, 5.46)
Primary tumor size
≤3 cm
 Limited 2,930 29.2 (27.5, 31.0) 187 57.1 (48.8, 64.6) 1.96 (1.68, 2.27)‡
 Distant 4,469 5.5 (4.8, 6.2) 67 11.3 (4.7, 20.9) 2.05 (0.98, 4.32)
>3 cm - ≤7 cm
 Limited 3,391 21.6 (20.1, 23.1) 255 38.9 (32.3, 45.3) 1.80 (1.50, 2.16)‡
 Distant 6,817 4.2 (3.7, 4.7) 210 3.7 (1.6, 7.0) 0.88 (0.41, 1.87)
>7 cm
 Limited 1,071 15.6 (13.3, 18.0) 117 37.0 (27.8, 46.3) 2.37 (1.76, 3.19)‡
 Distant 3,079 4.9 (4.1, 5.7) 135 12.6 (7.3, 19.5) 2.57 (1.55, 4.27)‡
Year of diagnosis
1992-2000
 Limited 6,660 18.9 (17.9, 19.9) 364 40.9 (35.5, 46.3) 2.16 (1.87, 2.50)‡
 Distant 14,006 3.5 (3.2, 3.8) 314 5.5 (3.2, 8.5) 1.57 (0.98, 2.53)
2001-2010
 Limited 5,410 23.0 (21.7, 24.2) 543 43.8 (39.1, 48.4) 1.90 (1.69, 2.14)‡
 Distant 14,997 4.4 (4.1, 4.8) 521 6.7 (4.6, 9.3) 1.52 (1.06, 2.19)‡
  1. Abbreviations: CI confidence interval, EPSCC extrapulmonary small cell carcinoma, No. number, RS relative survival, RSR RS ratio, SCLC small cell lung carcinoma, SEER-13 13 cancer registry areas of the Surveillance, Epidemiology and End Results (SEER) Program.
  2. * Based on microscopically confirmed cases of small cell carcinoma diagnosed during 1992–2010 and followed through 2011. To allow a general overview of stage across primary sites, we used the SEER historic stage variable that includes localized (confined to the organ of origin), regional (direct extension to adjacent organ/tissue or regional lymph nodes), distant (discontinuous metastases), and unspecified stages. We combined localized and regional stages into the category of “limited” stage and maintained the distant stage variable as defined in the SEER Program.
  3. Stage was not specified for 1,760 cases of SCLC (3-year RS (%) = 12.1, 95 % CI = 10.5, 13.8), and 162 cases of EPSCC (3-year RS (%) = 21.0, 95 % CI = 14.6, 28.2).
  4. ‡ 95 % CI excludes 1.00 (based on unrounded upper and lower CI), and RSR is significant (P < 0.05).